Skip to main content
. 2019 Aug 26;14(8):e0221500. doi: 10.1371/journal.pone.0221500

Fig 1. Study population selection.

Fig 1

Flowchart showing selection of the final study population of new users of warfarin, dabigatran, rivaroxaban or apixaban for non-valvular atrial fibrillation from 15 July 2013 to 31 December 2015 in Norway by linkage of nationwide registries.